Prostate cancer is cancer that occurs in the prostate. It is the most common cancer among men (after skin cancer). Unfortunately, metastatic castration-resistant prostate cancer (mCRPC) is still incurable.
Recently, Hunan Huateng Pharmaceutical Co., Ltd.(hereafter called Huateng Pharma) completed a series B financing of 117 million yuan. This round of financing was led by CITIC Securities, followed by Hunan Xingxiang Group, Shenzhen Hongfu No. 7, and Zhou Qilin, an academician of the Chinese Academy of Sciences.
Huateng Pharmac raised 50 million yuan in the series A round of funding led by Tianshili Capital's Boyi Fund and followed by Zhuhai Danchi Equity Investment Fund, and Hunan Dingteng Juzhi Investment Partnership.
Baloxavir marboxil, marketed as Xofluza, is a first-in-class, one-dose oral agent first approved by the FDA in 2018 for the treatment of acute, uncomplicated influenza in individuals 12 years and older, who have been symptomatic for less than 24 hours.